Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer
Clinical trial NCT02923180 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT02923180
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-02-14
- Primary completion
- 2020-08-11
- Enrollment
- 33
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.